Balyasny Asset Management
MLTX icon

Balyasny Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Balyasny Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,700
Closed -$213K – 3381
2025
Q3 		$213K Buy
+29,700
New +$1.55M ﹤0.01% 2708

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Balyasny Asset Management's MLTX Position: Q2 2026 in Review

Balyasny Asset Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 14% in Q2 2026, selling an estimated $2.77M and leaving 912,715 shares worth $17.8M. The position accounts for 0.02% of the portfolio, ranked #782.

Balyasny Asset Management first reported a position in MLTX in Q3 2022 and has held it in 16 quarters since. The position peaked at $36.1M in Q4 2023. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Balyasny Asset Management held 912,715 shares of MoonLake Immunotherapeutics worth $17.8M as of Q2 2026.
  • Balyasny Asset Management sold 152,895 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.77M.
  • MoonLake Immunotherapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #782 holding.
  • Balyasny Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2022 and has held it in 16 quarters since.
  • Balyasny Asset Management's MoonLake Immunotherapeutics position peaked at $36.1M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.